JNCI Journal of the National Cancer Institute
Oxford University Press · US · ISSN 00278874
趨勢摘要
Output rose while average citedness slipped.
Field-weighted citation impact moved from 4.18 to 2.56. Expect lower average citation performance per article than before. Output grew sharply while citation impact fell. If you prioritize citation visibility, weigh this trend in your decision. The share of top-10% cited papers moved from 49.3% to 29.3%. A smaller share of articles now reach the highest cited ranks, so plan dissemination accordingly. Recent titles increasingly carry multicancer · karisma · endoxifen · nrg · folfirinox. If your work matches these emerging terms it may align with recent topical coverage.
引用指標
以 Scopus 與 OpenAlex 的引用圖譜為基礎。本站不提供 Clarivate 的 JCR 影響係數(Impact Factor)。
發表量與被引用表現
看看發表量成長時,被引用表現是否跟著提升。
主題變化
比較近 24 個月(2024-09 – 2026-08)與再往前 24 個月(2022-09 – 2024-08)的佔比。
- Colorectal Cancer Screening and Detection6.0%→9.5%+3.4%p先前近期
- Cutaneous Melanoma Detection and Management0.0%→3.3%+3.3%p先前近期
- Chemotherapy-induced cardiotoxicity and mitigation0.0%→3.0%+3.0%p先前近期
- Pancreatic and Hepatic Oncology Research0.0%→2.7%+2.7%p先前近期
- Lung Cancer Diagnosis and Treatment0.0%→2.7%+2.7%p先前近期
- Genetic factors in colorectal cancer4.4%→0.0%−4.4%p先前近期
- Cancer Immunotherapy and Biomarkers7.3%→3.5%−3.7%p先前近期
- Prostate Cancer Treatment and Research2.8%→0.0%−2.8%p先前近期
- Cancer survivorship and care8.5%→5.9%−2.5%p先前近期
- Global Cancer Incidence and Screening10.5%→8.0%−2.5%p先前近期
近期常見用語
近期論文標題中,比以往明顯增加的用詞。
作者國家分布
並列比較近 24 個月(2024-09 – 2026-08)與再往前 24 個月(2022-09 – 2024-08)的佔比。
- US59.5%→51.8%−7.7%p先前近期
- GB6.4%→9.9%+3.5%p先前近期
- CA11.9%→9.2%−2.7%p先前近期
- FR5.3%→7.4%+2.0%p先前近期
- CN4.9%→6.1%+1.2%p先前近期
- NL0.0%→5.7%+5.7%p先前近期
機構刊登數 Top 5
2018 – 2026 期間,在這本期刊發表論文最多的前 5 個機構。
最新刊登論文
20依刊登日期排序的最新 20 篇,並非完整清單。
高引用論文
202018 – 2026 期間被引用次數最多的 20 篇。
資料截至 2026-09-05